Illumina (ILMN) — Company Research
Last Updated: 25 June 2026
Illumina is the company that built the modern genomics era. Its sequencers and the consumables that run on them underpin the majority of the world's DNA reading, from cancer research to newborn screening. After three turbulent years dominated by the costly GRAIL acquisition and subsequent spin-off, a Chinese export ban, and stagnant revenue, Illumina enters mid-2026 as a leaner, refocused "Core Illumina" with restored GAAP profitability, a refreshed NovaSeq X platform, and a fresh push into proteomics via the SomaLogic acquisition. This report walks through what the business does, how the numbers actually look from primary filings, where the risks sit, and what is scheduled next. For live pricing see our Live Charts, and for the macro backdrop our Economic Calendar.
1. Company Snapshot
| Field | Value |
|---|---|
| Company | Illumina, Inc. |
| Ticker | NASDAQ: ILMN |
| Sector / Industry | Healthcare — Life-Sciences Tools & Genomics |
| CEO | Jacob Thaysen (since September 2023) |
| Headquarters | San Diego, California, USA |
| Employees | Approximately 9,900 (FY2025) |
| Market cap | ~$26.9bn (June 2026) |
| FY2025 revenue | $4.34bn |
| FY2025 net income (GAAP) | $850m |
| FY2025 GAAP diluted EPS | $5.45 |
| FY2025 non-GAAP diluted EPS | $4.84 |
| Dividend | None |
2. Bull & Bear Case
Bull Case
- Dominant installed base: Illumina controls an estimated two-thirds or more of the global next-generation sequencing market by revenue, with roughly 900 high-throughput NovaSeq X systems installed by the end of 2025 — each one a multi-year annuity of consumable pull-through.
- Razor-and-blade economics: The bulk of revenue is recurring consumables (flow cells and reagents), which gives Illumina a sticky, high-margin base that grows as the installed base and procedure volumes expand.
- Profitability restored: With GRAIL divested, FY2025 swung back to a GAAP net income of $850m and $931m of free cash flow, and management guides FY2026 revenue growth of 4–6% with non-GAAP EPS of $5.15–$5.30.
- China overhang easing: Beijing lifted the export ban on Illumina sequencers in late 2025, removing one of the largest drags on the top line, even though the company stays on the Unreliable Entities List.
- Optionality in multiomics: The SomaLogic proteomics acquisition and a deep pipeline (spatial, single-cell, informatics) extend Illumina beyond DNA into adjacent high-growth markets.
Bear Case
- Stalled growth: Revenue has now fallen for three consecutive years (2023–2025), and ex-China organic growth is only low single digits — a long way from the double-digit growth investors once paid up for.
- Intensifying competition: Element Biosciences, Ultima Genomics, Roche's new SBX platform, and China's MGI are all attacking the high-throughput market that has historically been Illumina's fortress.
- China structural risk: Even with the ban lifted, Illumina remains on the Unreliable Entities List, instrument sales need approvals, and domestic Chinese rivals are taking share permanently.
- Academic and funding sensitivity: A large share of demand comes from research and government-funded labs, leaving Illumina exposed to NIH budget pressure and a "muted" 2026 academic environment management has flagged.
- Premium valuation on flat earnings: At roughly 32x trailing GAAP earnings for a business with stagnant revenue, the multiple leaves little margin for execution missteps.
3. Business Segments
Following the GRAIL spin-off in June 2024, Illumina reports as a single "Core Illumina" operating segment, but its revenue disaggregates clearly between recurring product sales and services, with proteomics now a new emerging line.
| Segment | % of FY2025 revenue | What it is |
|---|---|---|
| Sequencing products (consumables & instruments) | 85% ($3.71bn) | Flow cells, reagents and sequencing instruments — the NovaSeq X, NextSeq and MiSeq families. Consumables are the recurring, high-margin core. |
| Genomic services & other | 15% ($0.63bn) | Sequencing-as-a-service, instrument service contracts, genotyping arrays and partnership/licensing revenue. |
| Proteomics (SomaLogic, from Q1 2026) | Emerging (~1.5–2% guided) | SomaScan proteomics assays acquired in January 2026, extending Illumina from DNA into multiomics. |
4. Business Model
How Illumina makes money: Illumina sells DNA-sequencing instruments at relatively modest margin, then earns the bulk of its profit on the proprietary consumables — flow cells and reagents — that must be bought to run every experiment. This razor-and-blade structure means each instrument placed becomes a multi-year stream of high-margin consumable revenue tied to how much customers sequence.
Unit economics: Gross margin ran at roughly 66% of revenue in FY2025, and consumables carry structurally higher margins than instruments, so profitability improves as the mix shifts toward pull-through on an installed base of tens of thousands of systems worldwide.
The moat: Illumina's advantage rests on accuracy, cost-per-genome leadership, a vast installed base with high switching costs, an entrenched software and content ecosystem, and the regulatory validation built into clinical workflows. The bear question is whether newer entrants can erode that lead at the high-throughput end.
5. Financial Health
All figures below are taken from Illumina's audited annual results and quarterly earnings releases. FY2025 ended 28 December 2025. Note the GRAIL discontinuity: GRAIL was spun off on 24 June 2024, so 2021–2023 figures are on a consolidated basis (including GRAIL and its large goodwill impairments), while 2024–2025 reflect the continuing "Core Illumina" business.
| Fiscal Year | Revenue | YoY % | GAAP EPS | Adjusted EPS | Dividend/share | Long-term debt (YE) |
|---|---|---|---|---|---|---|
| 2021 | $4.53bn | +39.7% | $5.04 | $5.90 | $0.00 | $1,695m |
| 2022 | $4.58bn | +1.3% | $(28.00) | $2.12 | $0.00 | $1,487m |
| 2023 | $4.50bn | −1.7% | $(7.34) | $0.86 | $0.00 | $1,489m |
| 2024 | $4.37bn | −2.9% | $(7.69) | $4.16 | $0.00 | $1,490m |
| 2025 | $4.34bn | −0.7% | $5.45 | $4.84 | $0.00 | $1,490m |
Notes: 2021 YoY reflects the COVID-rebound and the partial-year consolidation of GRAIL. FY2022 GAAP EPS of $(28.00) includes roughly $(24.93)/share of GRAIL goodwill impairment. The 2024 Adjusted EPS of $4.16 is on the continuing Core Illumina basis. Long-term debt is the non-current term/convertible debt at year-end; Illumina pays no dividend.
| Quarter | Revenue | Adjusted EPS | GAAP EPS |
|---|---|---|---|
| Q1 FY2026 | $1.09bn | $1.15 | $0.87 |
| Q4 FY2025 | $1.16bn | $1.35 | $2.16 |
| Q3 FY2025 | $1.08bn | $1.34 | $0.98 |
| Q2 FY2025 | $1.06bn | $1.19 | $1.49 |
| Q1 FY2025 | $1.04bn | $0.97 | $0.82 |
| FY2025 total | $4.34bn | $4.84 | $5.45 |
The balance sheet is sound: at year-end FY2025 Illumina held $1.63bn in cash and short-term investments against $1.99bn of total term debt, and generated $1.08bn of operating cash flow.
6. Valuation
Raw metrics, June 2026. Not opinions on whether the stock is cheap or expensive.
| Metric | Value |
|---|---|
| Market cap | ~$26.9bn (≈153m diluted shares × $176.16) |
| Enterprise value | ~$27.3bn (market cap $26.9bn + total debt $1.99bn − cash & ST investments $1.63bn per FY2025 balance sheet) |
| Trailing P/E (GAAP) | ~32.3x ($176.16 / FY2025 GAAP EPS $5.45) |
| P/E (forward) | ~33.7x ($176.16 / FY2026 non-GAAP guidance midpoint $5.225) |
| P/S (TTM) | ~6.1x (market cap / TTM revenue ~$4.39bn) |
| EV/EBITDA (TTM) | ~25.3x (EV $27.3bn / EBITDA ~$1.08bn; EBITDA = FY2025 operating income $807m + D&A $270m) |
| P/FCF | ~28.9x (market cap $26.9bn / FCF $931m; FCF = FY2025 operating cash flow $1,079m − capex $148m) |
| 52-week high | $177.76 |
| 52-week low | $88.00 |
| Short interest (% of float) | ~4.7% (≈7.2m shares) |
| Days to cover | ~3 days |
7. What Are They Building
Illumina's roadmap centres on extending its sequencing lead while broadening into multiomics. The NovaSeq X platform continues to ramp, driving down cost-per-genome and pulling through more consumables. Beyond DNA, the company is pushing into proteomics through the January 2026 acquisition of SomaLogic's SomaScan assays, building out spatial and single-cell capabilities, and investing heavily in informatics and AI-driven analysis to keep customers inside its software ecosystem. Management has also prioritised operating-margin expansion and roughly $100m of cost reductions following the China import disruption, alongside continued investment in clinical and oncology testing menus that expand the regulated, reimbursable end of the market.
8. Competitive Landscape
Illumina remains the clear leader in next-generation sequencing, but the competitive set is widening at both the long-read and high-throughput ends of the market.
| Peer | Market cap (June 2026) | Key 2025 metric / position |
|---|---|---|
| Thermo Fisher Scientific (TMO) | ~$184bn | Diversified life-sciences giant; Ion Torrent NGS platform competes at the lower-throughput end. |
| Oxford Nanopore (LSE: ONT) | ~£1.1bn (~$1.5bn) | Real-time, portable long-read nanopore sequencing; fast-growing challenger. |
| Pacific Biosciences (PACB) | ~$0.3bn | HiFi long-read sequencing for high-accuracy genomics; niche but technically differentiated. |
Newer entrants — Element Biosciences, Ultima Genomics, Roche's SBX platform and China's MGI — are also targeting the high-throughput segment that has historically been Illumina's stronghold.
9. Leadership & Ownership
Illumina is led by CEO Jacob Thaysen, who took the role in September 2023 and has driven the GRAIL divestiture, cost discipline and the multiomics pivot. Recent insider activity has been confined to routine equity-compensation events rather than discretionary open-market trading.
| Name | Date | Type | Shares | Price | Value | Plan Type |
|---|---|---|---|---|---|---|
| Jacob Thaysen (CEO) | 12 Feb 2026 | PSU vesting (acquire) | 13,264 | $0.00 | n/a | Performance award |
| Jacob Thaysen (CEO) | 12 Feb 2026 | Shares withheld for tax | 5,470 | $114.44 | ~$0.63m | Tax withholding |
| Jacob Thaysen (CEO) | 12 Feb 2026 | Annual equity grant | 25,734 | $128.24 | ~$3.30m | RSU grant |
These are routine compensation events; no material insider open-market buying or selling has been reported in 2026.
10. Key Risks
- Geopolitical / China (Macro): Illumina remains on China's Unreliable Entities List; instrument sales require approvals and domestic rivals continue to take share, structurally shrinking a once-major market.
- Competition (Operational): Element, Ultima, Roche and MGI are attacking the high-throughput sequencing market, threatening Illumina's pricing power and share over time.
- Revenue stagnation (Financial): Three consecutive years of revenue decline raise the question of whether the core market has matured faster than expected.
- Funding sensitivity (Macro): Heavy reliance on academic and government-funded research labs exposes Illumina to NIH budget cuts and a muted 2026 academic spending environment.
- Integration risk (Operational): The SomaLogic proteomics acquisition takes Illumina into an adjacent market it must integrate and commercialise without distraction.
- Tariffs & supply chain (Macro): Cross-border tariffs and reliance on global manufacturing can pressure margins and complicate the China recovery.
- Litigation (Regulatory): Residual GRAIL-related litigation and ongoing patent disputes carry contingent costs.
11. Recent Developments
- 30 Apr 2026 — Q1 FY2026 beat and raise. Illumina reported revenue of $1.09bn (up 4.8%) and non-GAAP EPS of $1.15, and raised full-year revenue guidance to roughly $4.57bn with non-GAAP EPS of $5.15–$5.30.
- 12 Feb 2026 — FY2025 results. Full-year revenue of $4.34bn, GAAP diluted EPS of $5.45 and non-GAAP EPS of $4.84, with $931m of free cash flow.
- 30 Jan 2026 — SomaLogic acquisition closed. Illumina completed its $350m cash purchase of the SomaLogic proteomics business from Standard BioTools, accelerating its multiomics strategy.
- Nov 2025 — China lifts export ban. China's Ministry of Commerce lifted the ban on importing Illumina sequencers; the company remains on the Unreliable Entities List, requiring approvals for instrument purchases.
12. Key Dates to Watch
- 30 Jul 2026 — Q2 FY2026 earnings release (expected)
- Expected Oct 2026 — Q3 FY2026 earnings release
- Expected Feb 2027 — Q4 and full-year FY2026 results
Discuss this research with other members in our Forum.
Disclaimer: This research is produced by ChartsView for educational and informational purposes only. It does not constitute financial advice or a recommendation to buy or sell any security. All information is sourced from publicly available company filings, press releases, and official data. ChartsView does not use analyst opinions or third-party ratings. Always conduct your own due diligence and consider your personal financial situation before making investment decisions. Past performance is not indicative of future results.
Loading research report…
13. Thesis Verdict
The central thesis. Illumina designs and sells DNA-sequencing systems and earns the bulk of its profit on the proprietary consumables those systems consume, a razor-and-blade model sitting atop a dominant installed base. In FY2025 it generated $4.34bn of revenue, swung back to a GAAP profit of $850m ($5.45 diluted EPS) and $931m of free cash flow, and guides FY2026 revenue growth of 4-6% with non-GAAP EPS of $5.15-$5.30. The near-term driver is the recovery of China sales after Beijing lifted its sequencer export ban, plus the NovaSeq X ramp and a new proteomics push via SomaLogic.
What would confirm or break it. Confirmation would come from a return to sustained organic revenue growth and continued margin expansion across upcoming quarters. The thesis would weaken if Chinese competition and the Unreliable Entities List permanently erode that market, if newer high-throughput rivals take share, or if revenue stagnation persists despite the cost actions management has taken.
Watchpoints
- ConfirmsQ2 FY2026 earnings (35 days) landing in line with or above management guidance.
- ConfirmsEvidence supporting the "Dominant installed base:" thesis continuing to build across subsequent filings.
- InvalidatesMaterialisation of the "Geopolitical / China (Macro):" risk, or any disclosure that fundamentally alters the capital-return or growth profile stated by management.
Diagnostic grid
Generated by ChartsView research tooling. Thesis strength measures how well the evidence in this report supports the company's stated thesis — it is NOT a buy/sell rating or price target. ChartsView is not authorised by the FCA to provide regulated investment advice. Generated 25 Jun 2026.